Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

12.62 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,020
Open	12.62
Bid (Size)	12.33 (100)
Ask (Size)	13.21 (600)
Prev. Close	12.62
Today's Range	12.62 - 12.62
52wk Range	3.430 - 15.79
Shares Outstanding	68,575,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting

October 19, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

August 31, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Performance

52-Week Range 20.1% below 52-week high

12.62

3.4352W Low 15.7952W High

1 Week 11.4% below 1-week high

11.991W Low 14.251W High

Alpha Tau Medical Ltd. - Ordinary Shares (DRTS) traded between $3.43 and $15.79 over the past 52 weeks and last traded at $12.62, 20.1% below its 52-week high. Over the past week it ranged between $11.99 and $14.25.

Past 12 Months

-8.2%

-18.6%

-6.3%

+55.6%

+161.3%

+215.5%

1W -$1.12

1M -$2.88

3M -$0.85

6M +$4.51

YTD +$7.79

1Y +$8.62

DRTS was +215.5% over the past year, +55.6% over six months, +161.3% year to date, -8.2% in the last week.

12 Months vs Market

DRTS

+215.5%

DIA

+11.1%

SPY

+14.2%

QQQ

+17.5%

IWM

+9.3%

Over the past 12 months DRTS returned +215.5% versus DIA (Dow) +11.1%, SPY (S&P 500) +14.2%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +9.3%.

Volume & Liquidity 0.01× 3-mo avg

Today 3,020 3-mo avg 550.9K

598.9K

468.9K

550.9K

721.4K

YTD

582.9K

488.8K

DRTS most recently traded 3,020 shares against a 3-month average daily volume of 550.9K.

More News

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's

July 21, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

July 15, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

June 23, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

June 11, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

June 03, 2026

From Alpha Tau Medical Ltd.; Tolmar Inc.

Via GlobeNewswire

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

June 01, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears ↗

May 29, 2026

Via MarketBeat

Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study ↗

May 11, 2026

Via MarketBeat

Get insights into the top gainers and losers of Monday's pre-market session. ↗

May 11, 2026

Via Chartmill

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

May 11, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

May 08, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab

May 05, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

May 04, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies

April 27, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

April 23, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

April 23, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

March 16, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

February 24, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

January 06, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

January 05, 2026

From Alpha Tau Medical Ltd.

Via GlobeNewswire

In today's session, these stocks are experiencing unusual volume. ↗

December 11, 2025

Via Chartmill

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

December 09, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

December 04, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Ordinary Shares publicly traded?

Yes, Alpha Tau Medical Ltd. - Ordinary Shares is publicly traded.

What exchange does Alpha Tau Medical Ltd. - Ordinary Shares trade on?

Alpha Tau Medical Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares?

The ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares is DRTS on the Nasdaq Stock Market

What is the current price of Alpha Tau Medical Ltd. - Ordinary Shares?

The current price of Alpha Tau Medical Ltd. - Ordinary Shares is 12.62

When was Alpha Tau Medical Ltd. - Ordinary Shares last traded?

The last trade of Alpha Tau Medical Ltd. - Ordinary Shares was at 10/19/26 04:00 PM ET

What is the market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares?

The market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares is 865.42M

How many shares of Alpha Tau Medical Ltd. - Ordinary Shares are outstanding?

Alpha Tau Medical Ltd. - Ordinary Shares has 865M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.